mimetic oral formulations of the actions of bariatric surgery with intestinal y-deviation of roux on the ileal brake; compositions, methods of treatment, diagnosis and systems for treating manifestations of metabolic syndrome, including insulin resistance, fatty liver disease, hyperlipidemia, and type 2 diabetes.

摘要

Abstract: "Mimetic oral formulations of the actions of bariatric surgery with ileal brake roux-y-intestinal deviation; compositions, methods of treatment, diagnosis and systems for treatment of manifestations of metabolic syndrome, including insulin resistance, fatty liver disease, hyperlipidemia. and type 2 diabetes, as the present invention is pharmaceutical compositions, methods of treatment and related diagnostics, and computer implementable systems, which address the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity , insulin resistance, hypertension, atherosclerosis, fatty liver disease and certain chronic inflammatory states. In a further aspect of the invention, the compositions and treatment methods are calibrated for the ileal brake in response to surgical intervention, such as, for example, bariatric surgery with Roux-en-Y intestinal shift, to activate the ileal brake acting on the gastrointestinal tract and liver of a mammal to control the manifestations of the metabolic syndrome and thus reverse or diminish the cardiovascular damage (arteriosclerosis, hypertension, lipid accumulation and the like) resulting from the progression of the metabolic syndrome. The net benefit is the potential for treating all common manifestations of metabolic syndrome, including type 2 diabetes and obesity, with a drug that contains glucose as an ileal brake activating agent. The ileal brake is the controller for the progression of the metabolic syndrome, and both bariatric surgery with Roux-en-Y intestinal diversion and oral formulation beneficially affect the manifestations of the metabolic syndrome via this pathway. Combined medications are also presented, which act synergistically on the ileal brake and on the manifestations of the metabolic syndrome. in other aspects, the invention provides ileal brake stimulating hormone release compositions, methods of treatment, diagnosis and related systems useful in selective appetite control, stabilizers of insulin and blood glucose levels, as well as the treatment of gastrointestinal disorders of This is similar to bariatric surgery with Roux-en-Y intestinal diversion, but having at least 20% of the power to stimulate the human ileal brake hormonal response. 1/2